A blood test to diagnose ALS.
A blood test to diagnose amyotrophic lateral sclerosis (ALS) could be widely available within two years.
Currently, ALS is diagnosed through a clinical examination by a neurologist but distinguishing it from other neurological diseases requires tracking symptom progression.
This is problematic, as the average survival time in ALS is approximately three years, meaning many patients deteriorate significantly before receiving a definitive diagnosis.
Initial misdiagnosis rates range as high as 68%, delaying treatment and causing patients to be passed between specialists, increasing anxiety, unnecessary interventions, and costs.
A simple blood test for ALS would be a game-changer. It would speed up diagnosis, reduce anxiety, lower costs, and support the development of new drugs. Given the high misdiagnosis rate, a negative result would also be highly valuable.
Extracellular vesicles are nano-sized particles that circulate in the blood, are secreted by all cells, an contain microRNA.
Researchers at the Brain Chemistry Labs in Jackson, Wyoming, reported today in Brain Communications that they have identified an ALS-specific biomarker, an “ALS fingerprint,” in the blood. The biomarker of eight microRNAs (miRNAs) can be detected via a simple blood draw.
Using next-generation sequencing and real-time PCR, the team analyzed blood samples from patients with ALS, Primary Lateral Sclerosis (PLS), Parkinson’s disease (PD), and healthy individuals.
The eight microRNA ALS fingerprint accurately detects ALS with as high as 98% accuracy and can separate ALS from PLS and PD.
“Faster diagnoses will allow for earlier treatment, which will improve patient outcomes,” says Sandra Banack, lead author of the study.
To confirm its reliability, the biomarker was tested across four different patient groups, in two labs, with various technicians and collection methods. The ALS fingerprint consistently produced reliable results.
Researchers believe this blood test could assist neurologists in diagnosing ALS and complement current clinical assessments.
Dr. Paul Alan Cox, Executive Director of Brain Chemistry Labs, hopes to secure a diagnostic company partnership and make this test widely available to neurologists within 18 to 24 months.
————
Brain Chemistry Labs is a 501(c)(3) not-for-profit organization in Jackson, Wyoming, that seeks to discover new ways to prevent, diagnose and treat ALS, Alzheimer’s, Parkinson’s and other serious brain diseases.
The Brain Communications paper, “A microRNA diagnostic biomarker for amyotrophic lateral sclerosis” (DOI 10.1093/braincomms/fcae268) can be accessed here.
Rep. Hageman Visits Wyoming Drug Discovery Lab Brain Chemistry Labs
Dr Sandra Banack and Rep. Hageman.
U.S. Representative Harriet Hageman visited Jackson-based Brain Chemistry Labs, Wyoming’s only drug discovery lab focused on diagnosing, treating, and preventing neurodegenerative diseases such as ALS, Alzheimer’s, Parkinson’s and other brain diseases.
During the lab tour, Senior Scientist Dr. Sandra Banack called out the team’s recent advances in ALS research, specifically regarding a blood diagnostic that uses only a single blood draw to diagnose disease with incredible accuracy.
“This Brain Chemistry Labs team has shown that these diseases can be slowed if not reversed, which is an enormous accomplishment. The research being done here in Wyoming has far-reaching impacts for millions everywhere suffering from these terrible diseases,” commented Representative Hageman.
Currently patients often wait as long as two years before receiving a definitive diagnosis, during which time the disease progresses and their condition declines. This new diagnostic will be of great benefit to patients and neurologists.
Representative Hageman commented that “better diagnosing and treating needs to be done for these diseases—I feel very strongly about that.”
Dr. Banack then discussed the work the team has underway on a blood diagnostic panel she hopes will someday be used as a tool by physicians to help identify those who may be at risk for developing neurodegenerative diseases, enabling earlier treatment and improved patient outcomes.
Dr. Banack also explained how the team had found a naturally occurring toxin that can trigger neurodegeneration by causing the characteristic protein misfolding.
In addition, the research at Brain Chemistry Labs has led to the discovery of a molecule that can significantly slow disease progression.
Dr. Banack also described the clinical trial currently underway at Houston Methodist on Mild Cognitive Impairment (MCI), a precursor to Alzheimer’s.
A presentation highlighting recent research advances followed the lab tour, including significant progress made using Wyoming violets to help turbocharge current treatment for glioblastoma, a lethal form of brain cancer with a grim prognosis. This novel approach will begin in vivo testing later this year, with the intent of starting human clinical trials thereafter.
The Jackson-based Brain Chemistry Labs team is supported by a global consortium of fifty team members across 27 disciplines, including neurologists, neuropathologists, biologists, chemists, biochemists, physiologists, ecologists, and epidemiologists.
Representative Hageman was genuinely interested in the research capabilities of the Brain Chemistry Labs, noting that the work coming out of the lab seems to hold much promise.
“This Brain Chemistry Labs team has shown that these diseases can be slowed if not reversed, which is an enormous accomplishment. The research being done here in Wyoming has far-reaching impacts for millions everywhere suffering from these terrible diseases,” commented Representative Hageman.
Dr. Banack was very grateful that the Congresswoman took time to visit, noting that “we deeply appreciate her excitement for our work and her interest in helping us improve patient outcomes.”
Governor Gordon Visits Wyoming Drug Discovery Lab Brain Chemistry Labs
Governor Gordon and Dr Sandra Banack at Jackson-based Brain Chemistry Labs.
Governor Mark Gordon visited Jackson-based Brain Chemistry Labs, Wyoming’s only drug discovery lab focused on diagnosing, treating, and preventing neurodegenerative diseases, including ALS, Alzheimer’s, Parkinson’s and other brain diseases.
In a lab tour led by senior scientist Dr. Sandra Banack, Governor Gordon commented that he was “fascinated by all this” as he was shown equipment that examines nanoparticles, small particles containing both DNA and RNA. As the tour continued, Governor Gordon remained very engaged and deeply interested in the research capabilities of the Brain Chemistry Labs.
The Brain Chemistry Labs team members explained each area of the lab and its significance to their work, which includes testing of water samples to determine levels of BMAA, a neurotoxin that can lead to the development of neurologic diseases; how using a protein found in violets is being synthesized and evaluated as a possible combination treatment for glioblastoma, a deadly form of brain cancer; and advances in a blood diagnostic test that can—with an unprecedented degree of accuracy—detect ALS, a particularly difficult disease to diagnose in a timely fashion accurately.
A presentation detailing recent advances in research followed the lab tour, including discussion of a current trial underway at Houston Methodist Hospital on Mild Cognitive Impairment (MCI), a precursor to Alzheimer’s, and plans for upcoming clinical trials on ALS and Parkinson’s.
Governor Gordon was impressed with the innovation coming out of this unassuming log cabin in Jackson. “This is phenomenal research and it’s very exciting to see this coming out of Jackson,” commented Governor Gordon. “It’s encouraging that the research being done here in Wyoming has international reach through the global consortium of the Brain Chemistry Labs,” he added.
Dr. Banack remarked that she was “very grateful that the Governor took time to visit our lab. We appreciate his enthusiasm for our work, and his solid understanding of our lab equipment made for a very stimulating discussion.”
Violet Research in Wyoming May Lead to Glioblastoma Cure.
Research on violets in Jackson Hole may lead to a powerful new treatment for glioblastoma.
Glioblastoma is an extremely dangerous form of brain cancer affecting both children and adults, with most patients perishing within nine to twelve months from diagnosis.
Surgery to remove the tumors is particularly difficult in children.
The FDA-approved chemotherapy TMZ is effective in only 50 per cent of cases, with rapid development of resistance to TMZ among the cancer cells.
Violet researcher Dr. Samantha Gerlach at Brain Chemistry Labs. Photo courtesy of Dr. Paul Alan Cox, Brain Chemistry Labs.
The Brain Chemistry Labs in Jackson has taken an innovative approach to glioblastoma treatment based on cyclotides—small circular peptides—extracted from violets.
Scientists there have demonstrated that in the test tube cyclotides can increase the power of TMZ to kill glioblastoma cells eight-fold.
Cyclotides, however, are found only in minuscule concentrations in violets. Brain Chemistry Labs researchers have found a way to produce in sufficient quantity synthetic versions of cyclotides from violets for further testing in mice.
A generous grant from the Dr. Denis R Lyman & Diane Kay Robards Lyman Foundation in Wyoming will enable cutting-edge research by the Brain Chemistry Labs in Jackson to develop and test a novel new glioblastoma treatment option.
Caption: Wyoming violets. Photo courtesy of Dr. Paul Alan Cox, Brain Chemistry Labs
This gift will enable Brain Chemistry Labs research fellow and New Orleans Dillard University Professor Dr. Samantha Gerlach to continue her studies on how to produce sufficient synthetic violet molecules to conduct human clinical trials.
Together with collaborator Dr. Christian Gruber of the Medical University of Vienna, the safety and effectiveness of the synthetic violet molecules will be determined as a step toward moving to human clinical trials.
The intended outcome is for mass-produced synthetic violet cyclotides to serve as a powerful tool to combine with current TMZ therapy to turbocharge glioblastoma treatment without creating resistance from the glioblastoma cells.
Neurotoxin BMAA found in dust from Great Salt Lake.
In a startling discovery, researchers have identified a chronic neurotoxin known as BMAA in dust particles from the Great Salt Lake's dried lakebed. This toxin, linked to neurodegenerative illnesses, has become a significant health concern due to its presence in windblown dust that reaches populous metropolitan areas along the Wasatch Front.
Dr James Metcalf collects dust samples from the Great Salt Lake.
The dust, enriched with heavy metals and now with identified cyanobacteria and their toxins, poses an unsettling environmental health risk.
Studies have indicated that chronic dietary exposure to BMAA can trigger ALS-type neuropathology, with the neurotoxin now considered the most substantial environmental risk factor for developing Amyotrophic Lateral Sclerosis (ALS).
Although BMAA exposure also causes laboratory animals to form Alzheimer’s-type neuropathology, its role in Alzheimer’s, as well as Parkinson’s, is not fully understood.
However, its connection to ALS has been corroborated by two recent epidemiological studies, marking it as the most robust environmental link to the disease thus far.
Notably, Dartmouth researchers observed a higher risk of ALS in residents living near cyanobacteria-infested rivers and lakes in New Hampshire, underscoring the potential hazard of BMAA exposure.
Studies have indicated that chronic dietary exposure to BMAA can trigger ALS-type neuropathology, with the neurotoxin now considered the most substantial environmental risk factor for developing Amyotrophic Lateral Sclerosis (ALS).
Furthering the concern, the nonprofit Brain Chemistry Labs in Jackson Hole has been monitoring BMAA and other cyanotoxins in water bodies like Lake Okeechobee and collaborating with the Calusa Water Keeper to study airborne cyanobacterial toxins in Florida.
International research groups from Sweden, China, and France are also investigating chronic BMAA exposure as an ALS risk factor.
While ninety percent of ALS cases are sporadic and ten percent familial, the threat posed by the inhalation of BMAA-laced dust remains unclear.
What is clear, however, is the urgent need for comprehensive studies to determine the potential increase in ALS risk due to exposure to the Great Salt Lake dust.
The study was published this week in the journal Toxins.
Cyanotoxin Analysis of Air Samples from the Great Salt Lake. James S. Metcalf, Sandra Anne Banack and Paul Alan Cox. Toxins 2023, 15(11), 659; https://doi.org/10.3390/toxins15110659
Wyoming Non-Profit Brain Chemistry Labs Hosts Global Symposium on Neurodegenerative Effects of BMAA
For Immediate Release
Jackson, Wyoming – October 26, 2023
The Jackson Hole-based Brain Chemistry Labs team recently hosted a symposium for its global consortium of scientists.
The symposium served as an opportunity for researchers from around the world to unveil their latest, often not-yet-published findings and freely discuss them among their interdisciplinary colleagues.
Dr. Paul Alan Cox presents an achievement award to Ph.D. student Katie Low for her studies of BMAA in the Greater Yellowstone Ecosystem with the Ricketts Conservation Foundation.
“We convened our extended network of neurologists, neuropathologists, chemists, biochemists, physiologists, epidemiologists, biologists, and Ph.D. students pursuing related fields. This event was particularly significant because it was our first in-person meeting since 2019,” commented Dr. Paul Alan Cox, Executive Director of the Brain Chemistry Labs.
With a focus on BMAA, a neurotoxin produced by cyanobacteria found in polluted lakes and rivers, the symposium explored how BMAA is produced and how it can be detected. BMAA has been found to cause a puzzling neurodegenerative disease among the Chamorro people of Guam, and is now considered by epidemiologists to be a risk factor for ALS. Scientists currently are attempting to determine if it could be a risk factor for Alzheimer’s and Parkinson’s disease.
“Each person in our consortium holds an important piece of the puzzle. Bringing together these scientists from distant countries helps build a more complete picture,” Senior Scientist Dr. Sandra Banack said.
“Our common goal is to make a meaningful impact on the lives of patients suffering from these brutal diseases.”
Bo Landin, the director of a documentary on this effort called Toxic Puzzle, narrated by Harrison Ford, has recently made the film available for free public viewing at www.brainchemistrylabs.org.
The Brain Chemistry Labs team has been testing a naturally occurring treatment option through various clinical trials, yielding promising results in terms of safety and effectiveness.
The team has also been successful in developing a diagnostic biomarker for ALS, which would accelerate diagnosis—and ultimately treatment—for patients with this serious disease.
Contact: Marya King, marya@ethnomedicine.org, 224-358-6578
Brain Chemistry Labs Elects Former California Mayor as New Board Chair
For Immediate Release
Jackson, Wyoming – October 30, 2023
Elizabeth Susan (Sue) Severson was recently unanimously elected to serve as the new Chair of the Board of Brain Chemistry Labs, a Jackson, Wyoming-based non-profit organization focused on neurodegenerative diseases.
With undergraduate degrees from BYU in microbiology and chemistry, Sue brings to her role a solid understanding of the mission, vision and goals of the Brain Chemistry Labs.
Ralph and Sue Severson with the Orbital Trap Mass Spectrometer they gifted to Brain Chemistry Labs in 2022.
Sue succeeds Chair and Founder Bill Egan, who recently retired from his position of Chair, which he held since the organization’s creation in 2006.
“I am honored and humbled to carry on the exceptional work Bill spearheaded, and am confident that, with support from my fellow board members, we will accelerate the accomplishments of the Brain Chemistry Labs in bringing much-needed treatments to ALS, Alzheimer’s and Parkinson’s patients,” remarked Sue.
Previously, Sue served Orinda, California as a two-term mayor, and also served as President of the Orinda Union School District. Additionally, Sue has served in leadership positions in several other non-profit organizations as well as within private business.
The Brain Chemistry Labs team is extremely grateful to Bill, its new Director Emeritus, for his bold leadership and vision since its inception.
A former Vice President of Johnson & Johnson, Bill fully supported the very early research of the Brain Chemistry Labs and helped shape the organization into what it is today.
Bill and the other board members enthusiastically endorsed Sue as their new Chair.
“Sue’s extensive and unique leadership experience, coupled with her commitment to generating new scientific discoveries to prevent, diagnose and treat neurodegenerative diseases, make her the optimal candidate to continue advancing the work of Brain Chemistry Labs, and we all are very excited to work with her in this new role,” commented Bill.
Contact: Marya King, marya@ethnomedicine.org, 224-358-6578
Toxic Puzzle Film Explains Dangers of Cyanobacteria Blooms
Ethnobotanist Dr. Paul Cox with centenarians in Ogimi village, Okinawa.
For Immediate Release
Jackson, Wyoming – September 1, 2023
Deadly cyanobacterial blooms increasingly contaminate lakes and reservoirs.
Narrated by Harrison Ford, the documentary film Toxic Puzzle: Hunt for the Hidden Killer graphically portrays the threats of cyanobacteria to human health, including an increased risk of ALS and Alzheimer’s disease.
Jackson-based Brain Chemistry Labs scientists Paul Alan Cox and Sandra Banack sought clues to a mysterious paralytic disease that killed 25 percent of the adults in two villages in Guam.
“Research on the island was like watching a murder mystery,” Cox said.
“Who was the killer of these innocent villagers?”
The culprit they unmasked: neurotoxins in cyanobacteria. As the most ancient forms of life on earth, cyanobacteria produced the oxygen in the earth’s atmosphere.
However, when pollution enters lakes and reservoirs, green cyanobacterial scums and floating crusts quickly appear.
Exposure to the resulting neurotoxins can trigger serious illness and even death in people and domestic animals.
Toxic Puzzle takes viewers from Guam to Ogimi village in a remote part of Okinawa, where ALS and Alzheimer’s are unknown. The diet consumed by the 100-year-old villagers provided the scientists with clues on how to prevent and treat serious brain diseases. Studies of the Ogimi diet at the Brain Chemistry Labs here in Jackson has led to clinical trials, creating new hope for patients and their families.
The film’s producers have provided a link for complimentary viewings of Toxic Puzzle at www.brainchemistrylabs.org.
Contact: Marya King, marya@ethnomedicine.org, 224-358-6578
Listen to us on Wyoming Public Radio!
Listen to Dr Paul Cox on Wyoming Public Radio – just in time for Old Bill's Fun Run!
Wyoming Couple Gifts Robot to Jackson Nonprofit Brain Chemistry Labs
Jackson, Wyoming – August 10, 2023
A generous gift from Dr. Denis R Lyman & Diane K Robards Lyman Foundation in Wyoming will bring rapid diagnosis of ALS much closer to the patients and their families.
Dr. Rachael Dunlop and Stewart Wood operate the new robot in the Brain Chemistry Labs.
This robot has sped up the validation process for the new microRNA ALS diagnostic test invented by the not-for-profit Brain Chemistry Labs.
The test is made from a standard blood draw in which small particles called extracellular vesicles released by the brain into the bloodstream are extracted.
Once concentrated, microRNA is extracted and sequenced.
The Brain Chemistry Labs team, led by Dr. Sandra Banack and Dr. Rachael Dunlop, discovered that a “fingerprint” of eight specific microRNAs distinguishes ALS patients from healthy people.
Using blood plasma samples from a Phase II clinical trial and the Centers for Disease Control National ALS Biorepository, the Brain Chemistry Labs team has reproduced this result four times.
The gift of a liquid-handling robot from The Dr. Denis R Lyman & Diane K Robards Lyman Foundation moves the diagnostic test one step closer to high throughput, making it an attractive prospect for licensing by a pharmaceutical company. Automated pipetting increases the speed of analysis and reduces human error during sample preparation.
Dr. Sandra Banack holds a sample of neurally enriched exosomes extracted from an ALS patient blood sample.
The scientists affectionately refer to the robot as “Nevada” after the first volunteer at the Brain Chemistry Labs. Nevada Robards was an early pioneer in the development of the whitewater rafting industry in Jackson Hole and was Diane Lyman’s mother.
Contact: Marya King, marya@ethnomedicine.org, 224-358-6578
How Would You Know if Neurotoxins are in Your Water?
Dr. James Metcalf in the Jackson, Wyoming laboratory. Photo credit: Dr. Paul Cox.
NEWS RELEASE 12-JUL-2023
Jackson Hole, Wyoming.
Dr. James Metcalf is pursuing a singular mission: developing a simple way that ordinary people can detect neurotoxins in their water supplies.
His polite manner and English accent belie his extraordinary professionalism.
With decades of training in elite institutions in the United Kingdom under his belt, Dr. Metcalf is recognized as one of the world’s top experts on water-borne toxins produced by cyanobacteria (also known as blue-green algae).
Travelling from the Thau lagoon in Southern France to coastal waters in Florida, Dr. Metcalf has collected water samples of green goo from lakes and estuaries worldwide for analysis at the Brain Chemistry Labs.
“The dream is for fishermen worried about their catch or ranchers worried about the water their cattle are drinking or even for recreation boaters or swimmers to have a simple and accurate way to test for BMAA and other neurotoxins,” Dr. Metcalf explains.
The methodologies and instrumentation in the lab are world-class but far beyond the abilities of the general population. Is it possible to invent a method of detection that does not require expensive equipment and extensive training?
The question is not academic. One toxin analyzed by Dr. Metcalf and his colleagues at the Brain Chemistry labs is of particular concern: BMAA triggers ALS and Alzheimer’s neuropathology in laboratory animals. How can individuals know if the green scum on their nearby pond or lake represents a neurological threat?
In the laboratory, Dr. Metcalf is building an immunoassay — a means of detecting a chemical through the test tube equivalent of an allergic reaction — to BMAA.
Immunoassays are routinely used to test for everything from COVID to pregnancy, but up to this point, no rugged and accurate immunoassays for BMAA have been available.
“The dream is for fishermen worried about their catch or ranchers worried about the water their cattle are drinking or even for recreation boaters or swimmers to have a simple and accurate way to test for BMAA and other neurotoxins,” Dr. Metcalf explains.
“In the laboratory, we can detect BMAA at very low levels, but I am trying to produce a simple test strip that can quickly alert an individual if a water body contains dangerous substances.”
The next steps are to prepare the technology for commercial use, a somewhat daunting task for a not-for-profit research institute like Brain Chemistry Labs.
Dr. Metcalf remains optimistic. “I am fairly confident that we can demonstrate a workable prototype for our biotech partners by the end of the summer,” he says. “It is a lot of work, but the benefit for the public will be immense.”
For further information: james@ethnomedicine.org, marya@ethnomedicine.org
307 734-1680
“Window into the brain”: a simple blood test to diagnose ALS is both robust and repeatable.
NEWS RELEASE 12-APR-2023
Jackson Hole, Wyoming.
ALS is a rare paralytic neurological disease that can impact people in the prime of life. Delays in receiving a definitive diagnosis can be devastating for patients who typically survive only 2–5 years post-diagnosis.
Currently, an ALS diagnosis requires multiple clinical examinations by a neurologist to determine disease progression. Unfortunately, misdiagnosis can occur, resulting in a delay of treatment.
A simple blood test for ALS that could be administered in a doctor’s office could accelerate referrals to neurological specialists for confirmation.
Based on analysis of small genetic fragments called microRNA, such a test has been developed by scientists at the non-profit Brain Chemistry Labs in Jackson Hole.
The test accurately identifies patients with ALS, based on analysis of blood samples from seventy ALS patients and seventy controls.
The microRNA is extracted from small particles in the bloodstream called extracellular vesicles, which protect the genetic cargo from degradation. A unique protein, L1CAM, allows concentration of particles that are diagnostic of ALS.
The test is robust and repeatable, as described this week in the journal RNA Biology.
“This test will assist neurologists in making a definitive and rapid diagnosis of ALS,” lead author Dr. Rachael Dunlop said.
Early diagnosis means patients can receive treatment sooner. “Time is of the essence for ALS patients,” explains co-author Dr. Sandra Banack.
The test can also be used in clinical trials to determine the efficacy of new drug treatments for ALS––a disease for which there is currently no cure.
The study, “L1CAM immunocapture generates a unique extracellular vesicle population with a reproducible miRNA fingerprint,” appears in the journal RNA Biology. https://doi.org/10.1080/15476286.2023.2198805
Building a Bridge Between Research & Patients.
Brain Chemistry Labs is a nonprofit research institute focused on serious brain illnesses. Our mission is to improve patient outcomes for people with serious brain diseases including ALS, Alzheimer’s, and Parkinson’s disease as well as glioblastoma.
These are considered by physicians and scientists to be among the most difficult diseases to understand and to solve.
We conduct state-of-the-art discovery research based on our small but highly qualified scientific staff in Wyoming and a broader 50 scientist consortium based at institutions throughout the world. In our scientific approach to these serious brain diseases, we focus on prevention, diagnosis, and treatment.
These connected pieces form a bridge from scientific research to better patient outcomes.
Treatments for serious illnesses.
We discovered that the naturally occurring amino acid L-serine slows protein misfolding in cell culture as well as in animal models.
We have proven in an FDA-approved Phase I clinical trial that L-serine is safe and indications that it slows the decline of ALS patients. It appears that our ongoing Phase II clinical trial of L-serine for ALS will confirm these findings.
We discovered that L-serine slows the formation of Alzheimer’s-type neuropathology in vivo.
We now seek to determine if it slows progression in Mild Cognitive Impairment—a precursor to Alzheimer’s disease—in an FDA-approved Phase II clinical trial at Houston Methodist Research Institute.
We have developed a model of Parkinson’s disease in marmosets, and are using this model to discover a new drug for Parkinson’s. Although levodopa helps Parkinson’s patients control some of their symptoms, it does not slow disease progression.
Rapid Diagnosis of ALS and Alzheimer’s Disease.
ALS patients often have to wait a year or more for an accurate diagnosis.
By analyzing blood samples from 170 ALS patients and 170 healthy individuals, we have discovered that sequences of a naturally-occurring molecule, miRNA, can assist neurologists in making a more rapid diagnosis of ALS.
Several months ago, we published our discovery of a molecule in blood samples from patients with early Alzheimer’s disease that can distinguish patients from healthy individuals at a very early stage.
Both of these discoveries will help patients and their families by allowing treatment to begin far more rapidly than ever before.
Dr. Sandra Banack analyzing blood samples in our Jackson Hole lab.
You Can Have an Impact by Making a Gift to Fight Disease.
Ralph & Sue Severson of Orinda, California, sought to use part of the proceeds from the sale of a small company they founded to improve outcomes for patients suffering from serious brain diseases. The Orbital Trap Mass Spectrometer they donated is now playing a crucial role in our analysis of new anti-glioblastoma peptides from violets.
Ralph & Sue Severson with the Orbital Trap Mass Spectrometer they gifted to BCL.
New Blood Test for ALS Promises Rapid Diagnosis
Dr. Sandra Banack at Brain Chemistry Labs preparing microRNA analysis of ALS patient blood samples.
Jackson, Wyoming — August 31, 2022
Patients with ALS, one of the most serious neurological diseases known, have been hampered by the time it takes to receive an accurate diagnosis. The period between the onset of symptoms and diagnosis averages over a year, precious time for a disease in which most patients die between 2-5 years from diagnosis. Researchers estimate that an inaccurate diagnosis occurs in 13-68% of cases.
A blood test for ALS based on microRNA—short segments of genetic material—found in particles called extracellular vesicles was developed in 2020 by scientists at the Brain Chemistry Labs. However, the precise protocols for shipping and storage of blood samples, which were maintained at -80°C, meant that many offices of doctors and neurologists would be unable to utilize the new test.
Today in an article appearing in the Journal of the Neurological Sciences, researchers from the Brain Chemistry Labs, Dartmouth Department of Neurology, and the Centers for Disease Control reported that they were able to replicate the original test with blood samples that were not collected and maintained under such stringent requirements.
Comparing blinded blood samples from 50 ALS patients from the U.S. National ALS Biorepository to 50 control participants, the genetic fingerprint of five microRNA sequences accurately discriminated between people with ALS and healthy individuals.
“We were surprised that the microRNA test worked for samples collected from various investigators under differing conditions,” said first author Dr. Sandra Banack.
Her colleagues Drs. Rachael Dunlop and Paul Cox concurred. “We expected samples would need to be stringently collected and stored,” said Dunlop. “Apparently, the extracellular vesicles shed into the blood protect their genetic cargo against different environmental conditions,” Cox said.
Verification of the new blood test is occurring at the Brain Chemistry Labs in Jackson Hole, which has applied for a patent on the test. They hope to find a diagnostic firm that can develop the test commercially for neurologists and physicians throughout the world.
Article reference: Banack SA, Dunlop RA, Stommel E, Mehta P, Cox PA. 2022. miRNA extracted from extracellular vesicles is a robust biomarker of amyotrophic lateral sclerosis. J Neurol Sci. https://doi.org/10.1016/j.jns.2022.120396
Contacts:
Dr. Sandra Banack, Tel: 307-734-1680, sandra@ethnomedicine.org
Dr. Rachael Dunlop, Tel: 307-734-1680, rachael@ethnomedicine.org
Dr. Paul Alan Cox, Tel: 801-375-6214, paul@ethnomedicine.org
We Think Differently About ALS, Alzheimer’s & Parkinson’s Disease.
Dr. Paul Alan Cox in the Jackson Hole laboratory.
One of the advantages of establishing a cutting-edge laboratory in the shadow of the Tetons is the freedom it gives our scientists to think differently about serious brain diseases.
Our focus is not on treating symptoms, but on discovering and disrupting the ultimate causes of brain diseases, particularly protein misfolding.
Our discovery of new diagnostic tests for ALS and Alzheimer’s, which promise to accelerate both diagnosis and treatment, resulted from our innovative approach.
Our testing of a naturally occurring amino acid, L-serine, to stop protein misfolds shows it to be safer, more effective, and cost-efficient than clearing β-amyloid plaques.
As a not-for-profit organization, we depend on your gifts to continue this important research. At a time of economic uncertainty, it is even more crucial that we seek new approaches to treat these most serious of diseases.
We are at a turning point, ready to make our discoveries available to patients worldwide. A gift from you right now will have a major impact.
Alzheimer’s Blood Diagnostic Test
Dr. Sandra Banack analyzing exosome test data.
At Brain Chemistry Labs, contrary to many other labs, we support the idea that misfolded β-amyloid and tau proteins are consequences rather than causes of Alzheimer’s disease.
As a result, we fear using β-amyloid and tau as blood-borne markers to diagnose and treat Alzheimer’s disease is too late in the disease process to modify the outcome.
We recently published our discovery of a unique metabolite that can diagnose Alzheimer’s at far earlier stages. Our test may even be predictive in pre-symptomatic cases.
As a way of increasing the sensitivity of the test, we will expand the number of blood samples in our cohort by incorporating blood samples from our upcoming clinical trial for Mild Cognitive Impairment, scheduled to commence in August, 2022.
ALS Blood Diagnostic Test Moves Forward with CDC Support and Triple Replication
Dr. Rachael Dunlop studies qPCR sequence data of microRNA segments for our ALS blood diagnostic
After we published our initial paper describing a diagnostic test for ALS, the Centers for Disease Control (CDC) agreed to send us 50 additional blood samples from patients diagnosed with ALS.
Comparing these to 50 blood samples from people who did not have ALS, we were extremely encouraged to find that five of the eight of our original microRNA sequences for ALS were verified. This gives us greater confidence in the sensitivity of our diagnostic assay.
To add to this, and importantly, the CDC blood samples were collected by physicians who did not have, as we did, -80°C freezers to protect the microRNA from degradation. Unlike our first 20 samples, these 50 were not collected following the stringent protocol we designed in our clinical trial.
This is important because it suggests the miRNA might be resistant to degradation, adding to the robustness and application of the assay.
The CDC has now sent us an additional 100 ALS blood samples which we will compare to 100 samples from people who have not been diagnosed with ALS.
This will confirm our ALS blood test if we get the same results.
Ultimately, we are hoping to attract the interest of a commercial diagnostic lab that has the resources to deliver this test into the hands of clinicians and patients who so desperately need a faster and more efficient way to diagnose ALS.
Validation of two diagnostic blood-marker tests for ALS and Alzheimer’s disease.
Dr. Rachael Dunlop runs our qPCR for microRNA disease diagnostics.
Our discoveries of blood diagnostic tests for ALS (based on microRNA) and Alzheimer’s disease (based on a unique metabolite) have now been published in prestigious scientific journals.
We are busily engaged in the painstaking process of validating these tests, using samples from the Centers for Disease Control for ALS, and previous samples from our Phase II early-stage Alzheimer’s trial.
We seek a pharmaceutical partner to commercialize these blood diagnostics so they can be made available to the public.
Our mission is to rapidly improve patient outcomes for serious brain diseases and thus, we want these diagnostic tests in the hands of neurologists as soon as possible.
Synthesis of an anti-glioblastoma (brain cancer) cyclotide from violets.
Synthesis of an anti-glioblastoma cyclotide from violets promises to advance our glioblastoma research by several years.
Glioblastoma is one of the most aggressive forms of brain cancer. Patients typically survive only a year after diagnosis.
We reported in the Journal of Natural Products that growth of human glioblastoma cells can be slowed by cyclotides, circular proteins extracted from violets.
By adding cyclotides, we were able to increase over eight-fold the effectiveness of the FDA-approved chemotherapy Temozolomide (TMZ).
We commissioned a state-of-the-art protein laboratory to produce a synthetic version.
Using our new Orbital Trap Mass Spectrometer, we are now testing small quantities of the synthetic molecules to ensure the same efficacy as those that occur in nature.
This synthetic approach promises to advance our glioblastoma research by several years.